MZEI is Breaking-Out – Up 23%

Medizone International, Inc. (OTCBB: MZEI) is a research and development company engaged in developing its AsepticSure™ technology to decontaminate and sterilize hospital surgical suites, emergency rooms, intensive care units, schools and other critical infrastructure. Following the current laboratory trials, hospital mockup and hospital beta testing will begin. Initial sales are targeted to commence in the 4th quarter of this year.

Profile Facts:

Symbol	MZEI
Exchange	Bulletin Board
Reporting Status	Fully Reporting
Shares Authorized	250m
Shares Issued	210m (est)
Years in Business	23

The Silent Epidemic

The chart you see above represents the Nosocomial infections outside intensive care units for U.S. hospitals in 2002.

As the notes that came from the source for this chart point out, Nosocomial infections are a huge problem in hospitals today. Although this data is from 2002, the situation has progressively become more serious. Here are the notes that accompanied the chart:

“From the total number of surgical site infections (SSI) obtained from the National Hospital Discharge Dataset and the National Nosocomial Infections Surveillance (NNIS) system, we subtracted the number of SSI among newborns and adults and children in intensive care units. The remaining SSI were among adults and children outside of intensive care units. From hospital-wide surveillance in NNIS, we had the distribution of infectons by major site and calculated the corresponding number of infections for pneumonias (PNEU), urinary tract infections (UTI), bloodstream infections (BSI), and other sites.”

The Impact of Nosocomial Infections in The United States

In 2002, there were approximately 1.7 million total infections. Of these:

• 33,269 occurred among newborns in high-risk nurseries
• 19,059 among newborns in well-baby nurseries
• 417,946 among adults and children in ICUs
• 1,266,851 among adults and children outside of ICUs.

In that year, the estimated deaths in U.S. hospitals were 98,987. Of these:

• 35,967 were for pneumonia
• 30,665 for bloodstream infections
• 13,088 for urinary tract infections
• 8,205 for surgical site infections, and
• 11,062 for infections of other sites.[1]

Nosocomial Infections are an International Problem

In a World Health Organization Survey of 55 hospitals in 14 countries representing four regions, an average 8.7% of hospital patients had nosocomial infections.

What are some of these Infections?

Here is a short list: C-difficile, E-coli, Pseudomonas aeruginous, MRSA and VRE, the main causative agents of hospital derived nosocomial infections.

How bad are some of these?

C. Difficile

C. Difficile is the most serious cause of antibiotic-associated diarrhea (AAD) and can lead to pseudomembranous colitis, a severe infection of the colon, often resulting from eradication of the normal gut flora by antibiotics. Some estimates place the added cost to the healthcare for C. Difficile alone at $17.6 million daily. The CDC estimates that C. Difficile ases in the US may reach 500,000 annually leading to potentially 30,000 deaths.

MRSA

Methicillin-resistant Staphylococcus aureus (MRSA) is a bacterium responsible for difficult-to-treat infections in humans. MRSA are by definition strains of Staphylococcus aureus that are resistant to a large group of antibiotics called the beta-lactams. CDC reported (JAMA, 2007) that the number of serious infections by MRSA in 2006 was close to 100,000, with approximately 19,000 associated deaths.

Current Methods at Sterilization Are Not Effective Enough

The solution is quite easy in one sense. Just eradicate the infectious diseases from the hospital and the problem is solved. That is prevention. The issue with this prevention is that present methods of cleaning, disinfection and sterilization are not effective. Current cleaning protocols for the sanitization of hospitals have become increasingly ineffective, resulting in an accumulation of deadly bacteria throughout facilities.

Recent research conducted by Microsearch Laboratories demonstrated that, after rinsing and cleaning prior to testing using standard procedures, a cleaning mop collected from a New York hospital was found to have in excess of 150,000 colonies of C. difficile. These results raise concerns about the efficacy of current cleaning and disinfecting procedures.

To make matters even worse, non-medical surfaces, e.g., carpets, bedding and curtains, porous materials in ceilings, once impregnated with highly resistant nosocomial pathogens (in particular, spore formers such as C. difficile) cannot be disinfected with currently available agents and processes. Over time, these pathogens may accumulate in dangerously high concentrations.

Current procedures for the sensitization of hospitals have become increasingly ineffective, resulting in an accumulation of deadly bacteria throughout facilities.

A Solution: Ozone is a Prime Candidate for use as a Sterilization Agent in Medical Facilities

Many people do not realize that ozone had a long and successful history of use as a potent anti-bacterial, anti-fingal and anti-viral agent. Ozone was first used as a disinfectant in 1881 by Dr. Kellog. In 1893 Ozone was used in the Netherlands for water purification. Presently, in excess of 3,000 municipalities around the world use Ozone for water purification.

Research conducted in New York City has also demonstrated that Ozone is effective against Legionella Bacteria, as well as pseudomonas populations in those water purification plants. Ohio State University (2001) demonstrated a 4 log difference in sporicidal action of Ozone vs. Vaporized Hydrogen Peroxide (6.1 log reduction for Ozone vs. 1.6 log reduction for VHP). Microsearch Laboratories has demonstrated (2007) that Ozone is 3,200 times more effective than chlorine.

Why Medizone?

• Medizone has a 23 year history in the field of medical therapeutics with Ozone.
• Medizone has initiated a joint program with Biozone Corporation to develop a state-of-the-art Ozone-based sterilization system (AsepticSure™) for medical applications.
• This technology will feature a new “Ozone Destruct” scrubbing system intended to rapidly detoxify hospital working spaces following exposure to Ozone.
• The Medizone technology (AsepticSure™) will have an Ozone producing capacity 4 times greater than what is thought to be necessary under normal hospital circumstances.
• The AsepticSure™ system will also include a gas vaporization component, and a stand alone Ozone scrubbing system, adaptable to all hospital environments and space requirements.

The Leadership:

Edwin G. Marshall – Chairman of the Board & Chief Executive Officer

Following a period of time in which he unsuccessfully attempted to influence and guide former management as a shareholder, a successful hostile proxy action was completed on June 12,1997.

Mr. Marshall took over as Chairman of the Board. Milton G. Adair, former President and CEO of Gull Laboratories was appointed Chief Executive Officer and President. Mr. Adair left the Company to pursue other interests in 1998. Mr. Marshall then took over the additional responsibility of Chief Executive Officer.

Mr. Marshall attended Santa Rosa Community College and the College of Marin, studying fire science and business administration. Until 1978 Mr. Marshall worked in the fire service in a city with a major chemical industrial complex, leaving with the rank of Captain. A successful private investor since 1973 in precious metals, securities and real estate, after leaving the fire service he went to work in the real estate brokerage business. From 1978 until 1995 he pursued various business interests in real estate brokerage, a vacuum forming business in the plastics industry, an industrial computer controls company, and an automobile and truck dealership. Since 1997 he has devoted all of his business time to management responsibilities with Medizone.

Michael E. Shannon, M.A.,M.Sc.,M.D. – Board Member & Director of Medical Affairs

Dr. Shannon received his medical degree from Queen’s University in Canada, which included advanced training in surgery and sports medicine. He also holds post-graduate degrees in neurochemistry and physiology. He has been actively engaged in applied medical research within these areas for over 27 years. He served in the Canadian Forces for 31 years retiring at the rank of Commodore (Brigadier General equivalent) as Deputy Surgeon General for Canada. During the first Gulf War, Dr. Shannon served as the senior medical liaison officer for all of the Canadian forces. In 1996 he assumed responsibilities within Health Canada for re-organizing the Canadian blood system. Working with both the provincial and federal governments he oversaw the development of a new corporate entity dedicated exclusively to the management of blood services in Canada. He was then appointed Director General for the Laboratory Centre for Disease Control, a position he held for three years. In December 2000, Dr. Shannon left the Canadian federal government to pursue a new career in industry. In that capacity he simultaneously directed a phase III clinical trial in Canada, the United States and Great Britain for an artificial blood substitute product. Following completion of that work he was asked to accept a special assignment with the Canadian Federal Government Auditor General’s office. His assignment being to conduct a cost benefit analysis of all government sponsored pharmacare programs and make recommendations directly to the Parliament of Canada. His assignment and presentation to Parliament was completed in November 2004. Dr. Shannon then served on a special assignment to the Canadian Public Health Agency (Center for Disease Control equivalent in the United States) as Senior Medical Advisor. His responsibility was to direct the rebuilding of the Emergency Medical Response Capacity for Canada. In this regard and under his direction, the largest emergency medical response exercise in the history of the country, involving the overnight construction of a mobile hospital, hundreds of doctors and thousands of patients, was successfully held in Toronto in December of 2007.

Dr. Shannon has been actively engaged in medical bio-oxidative (O3 based), research since 1987 and was directly responsible for the first human clinical trial to have ever been approved in North America which examined the efficacy of O3 delivered via minor autohemotherapy in the treatment of AIDS. He was also responsible for several primate studies utilizing O3 involving scientists from various departments within the Canadian Federal Government, as well as senior investigators from Medizone International and Cornell University. Dr. Shannon has served as the Senior Medical Advisor to Medizone International since 2002. In August of 2008 he accepted a position on the Board of Directors of Medizone International and assumed responsibility for medical affairs. In October 2008, he was additionally appointed the President of the Canadian Foundation for Global Health.

Richard Garret Solomon – Director and Executive Officer

Mr. Solomon first invested in Medizone in 1992. In 1995, Medizone New Zealand Limited (a partially owned subsidiary of Medizone International) was formed as a 50/50 joint venture. In January 1996, until February 1997, Mr. Solomon was a Director of Medizone International, Inc. and has rejoined the board as of May 1, 2000.

Mr. Solomon received a Bachelor of Commerce (University of Otago), Diploma of Business and Industrial Administration (University of Auckland), and is an Associate Chartered Accountant. His career has been in business and investment, and for 20 years he developed and ran his own private hospital operating company, Haven Care Hospitals Limited. He was a longstanding Board member and President of the New Zealand Hospitals Association. He lead the establishment of The New Zealand Council of Healthcare Standards, Inc.

Daniel D. Hoyt – Board Member

Mr. Hoyt graduated from Indiana University with a Bachelor of Science degree in General Business Administration in 1962. For the past 31 years, he has been involved in the life insurance and group benefits industry achieving both industry-wide and national company recognition for production and mentorship. Mr. Hoyt takes great pride in the relationships he has built through consultations with his business clients that range from large public companies to small private businesses. Throughout his career, he has served as mentor to many other entrepreneurs. Mr. Hoyt previously worked 7 years as an account executive at Merrill Lynch and as Chief Executive of two and Vice President of one Chamber of Commerce in Indiana. In addition to his board position with Medizone International, Mr. Hoyt is the Chairman of the Board of Biological Systems, Inc., a bio-cleansing, microbial remediation system dealing with natural animal fats and oil-based materials.

Mr. Hoyt is and has been very active in his community and church. These activities and positions include: current board member of the Indiana University Cancer Center Development Board; former board member and chair of Saint Mary of the Woods College, Terre Haute, IN; board chair of Our Lady of Fatima Retreat Center; twice chair of the Parents Association of Ball State University. Numerous other board and leadership positions include St. Elizabeth Home for Unwed Mothers, past president of Indianapolis Sierra Club, Prevent Blindness of Indiana; Indianapolis Business Development Foundation and Christamore Settlement House. He is currently chair of the Rebuild My Church Board of Visitors of Marian College, an active member of Immaculate Heart of Mary Catholic Church and a founding member of Pink Ribbon Connection, a newly formed group serving the needs of breast cancer patients and survivors in central Indiana (he is a 10-year survivor).

Steve M. Hanni – Chief Financial Officer

Mr. Hanni has served as Medizone International’s Chief Financial Officer since April 2, 2002.

Additionally, Mr. Hanni is the Audit Partner-in-Charge and Vice-President of the accounting firm, Stayner, Bates & Jensen, P.C., located in Salt Lake City, Utah. He was formerly a partner with the accounting firm, HJ & Associates, LLC, also located in Salt Lake City. HJ & Associates serves as the Company’s audit firm.

Mr. Hanni has worked closely with many different types of companies and organizations and has extensive auditing and consulting experience in the following industries: Mortgage Banking, Construction, Manufacturing, Oil and Gas companies, Retail, High Technology, Non-profit and Pension Plans.

In addition, Mr. Hanni has significant experience with Securities and Exchange Commission listed companies, including registration statements, public offerings and audits as well as providing management advisory services.

Contact information:

Medizone International, Inc. (OTC: MZEI)

Web:

http://www.medizoneint.com